La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Armstrong Flooring a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Armstrong Flooring..

Armstrong Flooring (OTC:AFIIQ) Azioni, Catena delle Opzioni

Armstrong Flooring Inc designs, manufactures, sources, and sells resilient and wood flooring products, which are primarily used for construction and renovation of residential, commercial, and institutional buildings. It operates through two segments namely Resilient Flooring and Wood Flooring. The Resilient Flooring provides a range of floor coverings for homes and commercial buildings under the Armstrong brand and the Wood Flooring segment provides hardwood flooring products under the Armstrong and Bruce brand names. Geographically, the group operates its business in the United States and also has its presence internationally, of which a majority of the revenue is derived from the United States.

ARMSTRONG FLOORING INC by Armstrong Flooring, Inc.

Armstrong Flooring Inc

RBC Capital analyst Pammi Bir maintains Allied Properties REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AP#TSX">AP</a>) with a Sector Perform and raises the price target from C$18 to C$19.

News

Price Target

Analyst Ratings

TSX:AP

TSX:AP/UN

RBC Capital Maintains Sector Perform on Allied Properties REIT, Raises Price Target to C$19

Macquarie analyst Paul Golding maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Outperform and raises the price target from $24 to $30.

NCLH

Macquarie Maintains Outperform on Norwegian Cruise Line, Raises Price Target to $30

BMO Capital analyst Evan Seigerman maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Market Perform and raises the price target from $53 to $57.

BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $57

RBC Capital analyst Maurice Choy reiterates AltaGas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALA#TSX">ALA</a>) with a Outperform and maintains C$40 price target.

Reiteration

TSX:ALA

RBC Capital Reiterates Outperform on AltaGas, Maintains C$40 Price Target

Crude prices are nearing full recovery from early-week losses, poised for a third consecutive daily gain on Friday amid escalating geopolitical tensions <a href="https://www.benzinga.com/topic/middle-east">in the Middle East.</a>
A report by <a href="https://www.axios.com/2024/10/31/israel-iran-planning-attack-iraq">Axios</a> on Thursday, citing two Israeli intelligence sources, indicates Iran may be preparing a major retaliatory strike from Iraq within days. Israeli intelligence reportedly anticipates an attack using numerous drones and ballistic missiles launched from Iraq.
Yet, U.S. officials told Axios that they remain uncertain whether Iran has finalized a decision to act. 
Iranian Revolutionary Guard Corps commander Hussein Salami warned on Thursday that Iran's response would be beyond any scenario Israel might anticipate.
In parallel, the conflict in Gaza intensified on Friday. Israeli airstrikes in Gaza killed more than 60 Palestinians within the past day, according to local medical sources. Israeli strikes also extended into the southern suburbs of Beirut.
Diplomatic efforts led by the U.S. struggled to make headway.
Market Reaction: West Texas Intermediate (WTI) crude prices, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), rose 2.4% on Friday. They reached $71 per barrel marking three days of upward momentum.
Since Wednesday, oil prices rebounded by over 5%. They nearly erased the declines seen earlier in the week caused by subdued attacks from Israel to Tehran.
U.S. energy stocks followed suit, with the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) climbing 1%. Notably, Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) rose by 0.6% and 3.9%, respectively, following quarterly earnings releases. 
While both oil giants topped earnings estimates, Exxon's revenue came in below expectations.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41687354/stocks-rebound-after-selloff-as-october-hiring-slump-fuels-interest-rate-cut-bets-10-etfs-to-wat">Stocks Rebound After Selloff As October Hiring Slump Fuels Interest Rate Cut Bets: 10 ETFs To Watch Friday</a></li>
</ul>
Image:

Large Cap

Specialty ETFs

Commodities

Politics

ETFs

Oil Prices Almost Recoup Week Losses As Iran Mulls Retaliatory Attack Against Israel Prior To US Elections

BMO Capital analyst Brian Pitz reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $230 to $236.

AMZN

BMO Capital Reiterates Outperform on Amazon.com, Raises Price Target to $236

Barrington Research analyst Alexander Paris maintains Stack Cap Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STCK#TSX">STCK</a>) with a Outperform and maintains C$13 price target.

TSX:STCK

Barrington Research Maintains Outperform on Stack Cap Gr, Maintains C$13 Price Target

RBC Capital analyst Greg Pardy maintains Athabasca Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATH#TSX">ATH</a>) with a Sector Perform and raises the price target from C$5.5 to C$6.

TSX:ATH

RBC Capital Maintains Sector Perform on Athabasca Oil, Raises Price Target to C$6

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $92 to $93.

LMAT

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $93

In the current session, the stock is trading at $108.41, after a 1.87% spike. Over the past month, United States Lime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USLM#NASDAQ">USLM</a>) stock increased by 19.59%, and in the past year, by 176.62%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730475025_0.png" alt="Past Year Chart" />

<h3>A Look at United States Lime P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
United States Lime has a better P/E ratio of 35.33 than the aggregate P/E ratio of 24.1 of the Construction Materials industry. Ideally, one might believe that United States Lime Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730475025_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

USLM

A Look Into United States Lime Inc's Price Over Earnings

Susquehanna analyst Bascome Majors maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Negative and lowers the price target from $30 to $28.

WERN

Susquehanna Maintains Negative on Werner Enterprises, Lowers Price Target to $28

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) with a Sector Perform and raises the price target from $10 to $11.

RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $11

<a href="https://news.bloomberglaw.com/us-law-week/warner-bros-discoverys-class-action-win-upheld-by-second-cir">https://news.bloomberglaw.com/us-law-week/warner-bros-discoverys-class-action-win-upheld-by-second-cir</a>
&nbsp;
<ul>
<li>Ruling affirms companies didn't mislead investors pre-merger</li>
<li>Investors had alleged stock drops were linked to misstatements</li>
</ul>
Warner Bros. Discovery Inc. and its top executives prevailed again on appeal in a securities lawsuit, after a panel of Second Circuit judges ruled Friday that investors couldn't show the entertainment giant misled them in disclosures before its merger took place.
The offering documents for the tie-up between Warner Bros. and Discovery allegedly left out key details about subscriber numbers, third-party licensing, and content release strategy, but those claims aren't sufficient to show "actionable omissions" in disclosures, the unsigned opinion said.
Investors had alleged that both Discovery and WarnerMedia stated they had scrutinized each other's investment plans and nonpublic financial ...
 &nbsp;

Legal

'Warner Bros. Discovery's Class Action Win Upheld by Second Cir.' - Bloomberg Law

Susquehanna analyst Charles Minervino maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and lowers the price target from $61 to $55.

Susquehanna Maintains Neutral on Valaris, Lowers Price Target to $55

Barrington Research analyst James Goss maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Outperform and raises the price target from $24 to $28.

IMAX

Barrington Research Maintains Outperform on Imax, Raises Price Target to $28

Susquehanna analyst James Friedman maintains LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Neutral and raises the price target from $50 to $58.

TREE

Susquehanna Maintains Neutral on LendingTree, Raises Price Target to $58

Susquehanna analyst Christopher Rolland maintains STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) with a Positive and lowers the price target from $35 to $33.

Susquehanna Maintains Positive on STMicroelectronics, Lowers Price Target to $33

Tigress Financial analyst Ivan Feinseth maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $58 to $64.

Tigress Financial Maintains Buy on Travel+Leisure, Raises Price Target to $64

<h2 class="wp-block-heading">Poland: Minister Of Health Signs Regulation Tightening Access To Medical Marijuana</h2>
Minister of Health Izabela Leszczyna signed a new regulation regarding narcotics and psychotropic substances on Oct. 29, significantly tightening access to medical marijuana. The new law will take effect seven days after the announcement, <a href="https://bezprawnik.pl/dostep-do-medycznej-marihuany/">writes</a> Bezprawnik, according to translation.
As <a href="https://www.benzinga.com/markets/cannabis/24/09/40877465/poland-tightens-medical-cannabis-rules-bans-telehealth-prescriptions">previously announced,</a> under the new law, medical marijuana prescriptions cannot be obtained through a telemedicine consultation, unless they are continuations of previously prescribed therapy. Only public facilities are allowed to issue remote prescriptions, while private clinics can't continue to prescribe the therapy remotely. The first medical marijuana prescription can only be obtained in person from a doctor.
The new rules come as the Ministry of Health says medical marijuana has been prescribed too easily.
New regulations will mostly affect less mobile patients, those living in smaller towns, and those who are unable to move around freely.
&#8220;The proposed content in the project aims to modify the amended regulation towards strengthening oversight over the prescription of controlled substances, thus reducing negative social phenomena associated with the misuse of these substances, including their excessive prescription, which leads to drug addiction requiring hospitalization or further pharmacological treatment," per the justification. "Besides the aforementioned health and social consequences, this also leads to increased public healthcare costs.&#8221;
In addition to cannabis products, the list of restricted substances includes morphine, fentanyl and oxycodone.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40754721/poland-ministry-of-health-supports-decriminalizing-possession-of-25-grams-of-cannabis-cultivatio">Poland Ministry Of Health Supports Decriminalizing Possession Of 25 Grams Of Cannabis, Cultivation Of 3 Plants</a>
<h2 class="wp-block-heading">Thailand: New Cannabis And Hemp Rules Expected To Be Finalized In A Year</h2>
Deputy Health Minister Dech-Is Khao Thong and his advisory team met this week with the Department of Thai Traditional and Alternative Medicine to discuss progress on the Cannabis and Hemp Act, <a href="https://www.hfocus.org/content/2024/10/32099">writes</a> Hfocus, according to translation. Thong said he needs to review details and scheduled a clause-by-clause discussion of the draft law.
Dr. Somrak Chingsaman, director-general of the department said it is expected that the law will be finalized within one year under the current administration. Among key items of the new draft law are:
<ul>
<li>Flowering parts are strictly for medical use.</li>
<li>Allowed for research purposes.</li>
<li>Products from flowering parts approved by the FDA can be used for consumption only, exempt from this law.</li>
</ul>
For other uses, such as textiles made from cannabis roots, branches, leaves, or stems, separate ministerial regulations will apply.
Improper medical use carries a 20,000-baht fine ($590) or one year in jail, while unauthorized sales will be punished with 100,000 baht or a one-year jail term.
In June, the Thai government decided to reverse its 2022 marijuana decriminalization decision by <a href="https://www.benzinga.com/markets/asia/24/06/39298781/thailand-unveils-proposals-making-cannabis-illegal-again-and-reduce-meth-possession-limits" target="_blank" rel="noreferrer noopener">relisting parts of the cannabis plant as a narcotic</a>, to go into effect January 1, 2025. While Thailand became the first country in Southeast Asia to allow legal the recreational use of marijuana, it has never been properly regulated, resulting in a proliferation of cannabis shops across the country. In July, however, Charnvirakul confirmed that then-Prime Minister Srettha Thavisin <a href="https://www.benzinga.com/markets/cannabis/24/07/39922637/thailand-will-not-re-criminalize-cannabis-prime-minister-agrees-to-regulate-industry-instead-wha" target="_blank" rel="noreferrer noopener">agreed that proper regulation is a better solution</a> than cannabis re-criminalization.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40713696/thai-deputy-prime-minister-optimistic-about-future-of-cannabis-industry">Thai Deputy Prime Minister Optimistic About Future Of Cannabis Industry</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Japan: Ultra-Strict THC Limits Set New Bar For CBD Products, Testing Global Suppliers</h2>
Japan recently imposed new rules regarding THC limits in CBD products and raw materials used to make them. The limits are among the strictest in the world, <a href="https://hemptoday.net/japans-strict-new-cbd-rules-force-suppliers-to-scramble-for-thc-free-formulations/">writes</a> Hemp Today. New rules are expected to take effect in December 2024.
The limits imposed are said to be 200 to 300 times stricter that the threshold in most other countries which usually allow 0.3% THC limit for all CBD products categories. Under Japan's new rules, THC is allowed at 10 mg/kg (= 0.001% = 10ppm) for oils and powders, and even stricter limits apply to aqueous solutions (0.10mg/kg = 0.00001% = 0.1ppm) and food products (1mg/kg = 0.0001% = 1ppm).
 Read Also: <a href="https://www.benzinga.com/markets/asia/24/10/41426708/70-of-german-physicians-can-now-prescribe-reimbursed-medical-marijuana-more-cannabis-updates-from-it">Japan: Updated Guidelines On THC Limits Don&#8217;t Address All Gaps, Says Expert</a>
The new THC limits pose significant challenges for foreign CBD suppliers already operating in Japan. Global companies such as PharmaHemp (Slovenia), Elixinol and CBDfx (U.S.), Endoca (Denmark), and Naturecan (UK) promote their products as THC-free, but Japan&#8217;s strict standards for transparency and rigorous compliance will put these claims to the test.
Continue reading on <a href="https://hemptoday.net/japans-strict-new-cbd-rules-force-suppliers-to-scramble-for-thc-free-formulations/">Hemp Today</a>.
Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/40845784/japan-criminalizes-cannabis-with-7-year-prison-sentence-medical-marijuana-remains-legal">Japan Criminalizes Cannabis With 7-Year Prison Sentence, Medical Marijuana Remains Legal</a>
<h2 class="wp-block-heading">Australia: Victoria's Medicinal Cannabis Patients Can Now Drive Without Fear Of Automatic License Loss</h2>
Medical marijuana patients in Victoria no longer have to fear that they will automatically lose their licence if caught driving with traces of the substance in their system, <a href="https://www.theguardian.com/australia-news/2024/nov/01/victoria-medicinal-cannabis-law-drivers">reported</a> The Guardian. Now, magistrates can exercise sentencing discretion for drivers who test positive for THC, provided they have a valid prescription for medical marijuana and are unimpaired while driving.
Previously, any detectable THC would lead to a mandatory six-month licence loss and fine, impacting users who took cannabis as prescribed for conditions like cancer or multiple sclerosis. Starting March 1, prescribed users can now explain their circumstances in court, allowing magistrates to decide on licence retention. However, driving with any THC trace remains an offence; the reform only adjusts sentencing discretion.
The change comes after Legalise Cannabis Victoria secured an amendment in the upper house on Thursday night
"Roadside saliva tests can detect tiny traces of THC more than a week after consumption, but these minuscule remnants have negligible impact on driving ability," said Legalise Cannabis MP David Ettershank. "Under the old law the mere presence of this remnant chemical meant a compulsory loss of licence for six months and a steep fine, but the driver had only taken their medicine as directed by their doctor."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40323963/australian-cannabis-producers-eye-european-market-especially-germany-and-france-marijuana-and-me">Australian Cannabis Producers Eye European Market, Especially Germany And France, Marijuana And Menstrual Pain Study Underway</a></li>
</ul>
Photo: Courtesy of OMfotovideocontent via Shutterstock

Cannabis

Victoria's Medical Marijuana Patients Can Now Drive Without Fear Of License Loss & More Cannabis Updates Around The Globe

Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares are<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679903/wayfair-announces-third-quarter-2024-results-reports-strong-profitability-in-tandem-with-further-m" rel="noreferrer noopener"> trading lower on Friday.</a>
The company reported third-quarter adjusted earnings per share of 22 cents, beating the street view of 13 cents. Quarterly sales of $2.884 billion (down 2%) topped the analyst estimate of $2.876 billion.
U.S. net revenue was $2.5 billion, down $60 million or 2.3% year over year. International net revenue was $372 million, with constant currency growth unchanged.
&#8220;Once again, we navigated a dynamic consumer environment while driving further discipline on costs to achieve a mid-single-digit Adjusted EBITDA margin for the second quarter in a row,&#8221; said&nbsp;Niraj Shah, CEO, co-founder and co-chairman, Wayfair.&nbsp;
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/41686535/can-blockchain-transform-finance-or-will-banks-like-citi-jpmorgan-wield-it-for-efficiency" rel="noreferrer noopener"> Can Blockchain Transform Finance Or Will Banks Like Citi, JPMorgan Wield It For Efficiency?</a>
Gross profit totaled $873 million (year-ago $917 million), representing 30.3% of total net revenue.
As of September 30, there were 21.7 million active customers, a 2.7% decrease from the previous year.
In the third quarter, 9.3 million orders were delivered, down 6.1% year over year.
&#8220;The core goal across each of our initiatives in 2024 is to foster customer loyalty and spur repeat business while driving economic value,&#8221; Shah added.
Mobile devices accounted for 63% of total orders delivered in the third quarter, up from 61.7% year over year.
The company exited the quarter with cash and equivalents worth $1.3 billion. Inventories as of quarter end totaled $81 million. Long-term debt at the end of the third quarter was $3.061 billion.
Needham analyst Bernie McTernan reiterated Wayfair with a <a target="_blank" href="https://www.benzinga.com/quote/W/analyst-ratings" rel="noreferrer noopener">Buy and maintained&nbsp;a $60&nbsp;price target.</a>
Price Action: W shares are trading lower by 2.6% to $41.72&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41683914/exxon-q3-earnings-11-3-billion-cost-savings-rising-production-dividend-hike-and-more" target="_blank" rel="noreferrer noopener">Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More</a></li>
</ul>

Comments

Armstrong Flooring

Armstrong Flooring (AFIIQ) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO